PainReform Ltd. (NASDAQ:PRFX) Short Interest Up 85.3% in February

PainReform Ltd. (NASDAQ:PRFX) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 63,000 shares, an increase of 85.3% from the February 13th total of 34,000 shares. Approximately 7.4% of the shares of the company are sold short. Based on an average daily volume of 3,210,000 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On PainReform

A hedge fund recently bought a new stake in PainReform stock. Apollon Wealth Management LLC purchased a new stake in PainReform Ltd. (NASDAQ:PRFX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 12,917 shares of the company’s stock, valued at approximately $43,000. Apollon Wealth Management LLC owned 9.23% of PainReform as of its most recent SEC filing. 37.28% of the stock is currently owned by hedge funds and other institutional investors.

PainReform Stock Up 5.3 %

Shares of NASDAQ:PRFX traded up $0.14 during trading on Friday, reaching $2.79. The stock had a trading volume of 73,408 shares, compared to its average volume of 1,106,445. PainReform has a 52 week low of $1.73 and a 52 week high of $61.20. The firm has a market capitalization of $2.44 million, a price-to-earnings ratio of -0.02 and a beta of 0.61. The stock has a fifty day simple moving average of $3.10 and a two-hundred day simple moving average of $2.96.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.